New study checks if kidney disease changes cancer drug safety

NCT ID NCT04953897

Recruiting now Disease control Sponsor: Taiho Oncology, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 35 times

Summary

This early-stage study tests an oral cancer drug (decitabine and cedazuridine) in 18 adults with acute myeloid leukemia, myelodysplastic syndromes, or solid tumors. Half have severe kidney impairment, half have normal kidneys. Researchers measure how the drug moves through the body and check for side effects over about 8 weeks. The goal is to see if the drug is safe and works the same in people with kidney problems.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

BIO1
WITHDRAWN

Vilnius, Lithuania
Centrum Badań Klinicznych Piotr Napora Lekarze Sp. p.
RECRUITING

Wroclaw, 51-162, Poland
Complex Oncology Center - Plovdiv - Base II
WITHDRAWN

Plovdiv, Bulgaria
Erebuni Medical Center
RECRUITING

Yerevan, Armenia
Hematology Center After Prof. R. Yeolyan (Adult Blood Disorders)
RECRUITING

Yerevan, Armenia
Hematology Center After Prof. R. Yeolyan (Clinic of Adults Oncology)
RECRUITING

Yerevan, Armenia
Hospital Clínico Universitario Virgen de la Arrixaca (Hematology Dept)
RECRUITING

Murcia, 30120, Spain
Hospital Clínico Universitario Virgen de la Arrixaca (Solid Tumor Dept)
RECRUITING

Murcia, Spain
Hospital Universitari Arnau de Vilanova
RECRUITING

Lleida, Spain
Hospital Universitari Dexeus - Grupo Quirónsalud
WITHDRAWN

Barcelona, Spain
Hospital Universitari i Politècnic La Fe
TERMINATED

Valencia, Spain
Hospital Universitario 12 de Octubre
WITHDRAWN

Madrid, Spain
Institutul Oncologic Bucuresti - Prof. Dr. Alexandru Trestioreanu
RECRUITING

Bucharest, 22328, Romania
Institutul Oncologic Prof. Dr. Ion Chiricuta
RECRUITING

Cluj-Napoca, 400015, Romania
MD Anderson
RECRUITING

Houston, Texas, 77030, United States
National Center of Oncology Named After V.A. Fanarjyan
RECRUITING

Yerevan, Armenia
START Barcelona - Hospital HM Nou Delfos
RECRUITING

Barcelona, 8023, Spain
START Madrid - CIOCC - HM Sanchinarro
RECRUITING

Madrid, 28050, Spain
START Madrid - Hospital Universitario Fundación Jiménez Díaz
RECRUITING

Madrid, 28040, Spain
START Rioja - Hospital de San Pedro
RECRUITING

La Rioja, 26006, Spain
Summit Clinical Research s.r.o
RECRUITING

Bratislava, 831 01, Slovakia

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

oral decitabine and cedazuridine (ASTX727)

What this could lead to

If successful, this study could show that the drug is safe and works similarly in patients with severe kidney impairment, allowing them to receive this treatment.

What could go wrong

This is a very early (Phase 1b), small study with only 18 participants. It focuses on drug levels and safety, not on curing the cancer. Results may not apply to all patients.

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia hematopoietic and lymphoid cell neoplasm myelodysplastic syndrome Myelodysplastic Syndromes neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA MYELODYSPLASTIC SYNDROMES MYELODYSPLASTIC SYNDROMES